August 7, 2025

The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial

Syqe®’s third study (2020) evaluated the SyqeAir Inhaler as a solution for safe, consistent, and low-dose medical cannabis treatment in patients with chronic neuropathic pain. Listen to the podcast.

J-Wire & AJN: SyqeAir Inhaler available free to Australian veterans

11/05/2025

SyqeAir Inhaler received the Australia’s TGA approval and included in DVA’s funding scheme — enabling eligible veterans to access the treatment at no cost.

Syqe® Begins Marketing Medical Cannabis Inhaler

20/06/2019

The new inhaler, which allows doctors to prescribe precise dosages, has received Ministry of Health approval in Israel.

The Coolest Cannabis Gadgets We’ve Ever Seen

15/03/2021

Cannabis gadgets have come a long way. Some of them provide precision dosing, and many combine state-of-the-art design and materials with craftsmanship that (sorry) puts your old gravity bong to shame.

Medical Cannabis

SyqeAir Inhaler

Useful Information

Media

Contact Syqe®

Phone. +972-3-376-7338
Email. info@syqemed.com
Syqe® Israel. syqe.co.il

Show Us Some Love

The site and the content therein are provided for general knowledge only and do not constitute advertising and/or medical, pharmacological, or professional advice, diagnosis, treatment, or other healthcare services that in any way generate a doctor-patient relationship and/or recommendation for treatment or products in general, and for medical cannabis products and/or SyqeAir inhaler in particular. You should make all medical or health-related decisions on the basis of professional advice from a licensed physician or qualified healthcare professional who is fully aware of your individual circumstances. For any questions regarding products, including medical cannabis products and/or the SyqeAir inhaler, please consult your attending physician and/or the pharmacist at the dispensing pharmacy. The use and reliance on all content appearing on this site are at your sole responsibility, and Syqe® will not be responsible for any decision or action taken by you as a result of relying on this site.

Day: August 7, 2025

The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial

Related Posts

J-Wire & AJN: SyqeAir Inhaler available free to Australian veterans

Syqe® Begins Marketing Medical Cannabis Inhaler

The Coolest Cannabis Gadgets We’ve Ever Seen